Wall Street analysts predict that Edwards Lifesciences Corporation (NYSE:EW) will announce $0.90 earnings per share for the current fiscal quarter, Zacks Investment Research reports. Nine analysts have provided estimates for Edwards Lifesciences Corporation’s earnings, with estimates ranging from $0.88 to $0.92. Edwards Lifesciences Corporation posted earnings of $0.75 per share during the same quarter last year, which would suggest a positive year over year growth rate of 20%. The company is expected to announce its next earnings report on Wednesday, February 7th.

According to Zacks, analysts expect that Edwards Lifesciences Corporation will report full year earnings of $3.75 per share for the current fiscal year, with EPS estimates ranging from $3.72 to $3.76. For the next financial year, analysts anticipate that the business will post earnings of $4.12 per share, with EPS estimates ranging from $3.79 to $4.28. Zacks Investment Research’s EPS calculations are an average based on a survey of analysts that that provide coverage for Edwards Lifesciences Corporation.

Edwards Lifesciences Corporation (NYSE:EW) last issued its quarterly earnings results on Tuesday, October 24th. The medical research company reported $0.84 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.86 by ($0.02). Edwards Lifesciences Corporation had a net margin of 22.47% and a return on equity of 27.22%. The firm had revenue of $821.50 million for the quarter, compared to analyst estimates of $833.85 million. During the same period last year, the company earned $0.68 EPS. The company’s revenue was up 11.1% compared to the same quarter last year.

Several brokerages have issued reports on EW. Canaccord Genuity reaffirmed a “buy” rating and issued a $155.00 price objective on shares of Edwards Lifesciences Corporation in a research report on Sunday, October 8th. Cowen and Company reaffirmed a “buy” rating and issued a $135.00 price objective on shares of Edwards Lifesciences Corporation in a research report on Thursday, October 12th. Barclays PLC lowered their price objective on shares of Edwards Lifesciences Corporation from $120.00 to $118.00 and set an “equal weight” rating for the company in a research report on Wednesday, October 25th. BidaskClub downgraded shares of Edwards Lifesciences Corporation from a “buy” rating to a “hold” rating in a research report on Friday, August 25th. Finally, Zacks Investment Research downgraded shares of Edwards Lifesciences Corporation from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 17th. Seven investment analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the company. The stock has an average rating of “Buy” and an average price target of $125.17.

ILLEGAL ACTIVITY WARNING: This news story was first posted by American Banking News and is the property of of American Banking News. If you are accessing this news story on another site, it was copied illegally and reposted in violation of United States and international trademark & copyright laws. The legal version of this news story can be read at https://www.americanbankingnews.com/2017/11/04/0-90-eps-expected-for-edwards-lifesciences-corporation-ew-this-quarter.html.

Edwards Lifesciences Corporation (EW) opened at $102.72 on Friday. The company has a quick ratio of 2.76, a current ratio of 3.49 and a debt-to-equity ratio of 0.33. The company has a market cap of $21.45 billion, a PE ratio of 28.08, a price-to-earnings-growth ratio of 1.82 and a beta of 0.46.

In related news, CEO Michael A. Mussallem sold 32,900 shares of Edwards Lifesciences Corporation stock in a transaction dated Monday, October 30th. The shares were sold at an average price of $100.93, for a total transaction of $3,320,597.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, VP Donald E. Bobo, Jr. sold 5,300 shares of Edwards Lifesciences Corporation stock in a transaction dated Monday, October 30th. The shares were sold at an average price of $101.12, for a total transaction of $535,936.00. The disclosure for this sale can be found here. Insiders sold 171,480 shares of company stock worth $18,855,915 over the last quarter. 2.13% of the stock is currently owned by company insiders.

A number of large investors have recently added to or reduced their stakes in the stock. BNP Paribas Arbitrage SA grew its holdings in Edwards Lifesciences Corporation by 43.6% during the third quarter. BNP Paribas Arbitrage SA now owns 137,404 shares of the medical research company’s stock worth $15,020,000 after acquiring an additional 41,694 shares during the period. FDx Advisors Inc. grew its holdings in Edwards Lifesciences Corporation by 28.0% during the third quarter. FDx Advisors Inc. now owns 17,831 shares of the medical research company’s stock worth $1,949,000 after acquiring an additional 3,902 shares during the period. Jennison Associates LLC grew its holdings in Edwards Lifesciences Corporation by 6.2% during the third quarter. Jennison Associates LLC now owns 1,033,376 shares of the medical research company’s stock worth $112,958,000 after acquiring an additional 60,318 shares during the period. Scout Investments Inc. grew its holdings in Edwards Lifesciences Corporation by 0.9% during the third quarter. Scout Investments Inc. now owns 229,855 shares of the medical research company’s stock worth $25,125,000 after acquiring an additional 2,127 shares during the period. Finally, Oregon Public Employees Retirement Fund grew its holdings in Edwards Lifesciences Corporation by 7.1% during the third quarter. Oregon Public Employees Retirement Fund now owns 52,856 shares of the medical research company’s stock worth $5,778,000 after acquiring an additional 3,493 shares during the period. 82.37% of the stock is currently owned by hedge funds and other institutional investors.

About Edwards Lifesciences Corporation

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Get a free copy of the Zacks research report on Edwards Lifesciences Corporation (EW)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Edwards Lifesciences Corporation (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.